The battery-free percutaneous sacral neuromodulation system has comparable efficacy to published rates for traditional sacral neuromodulation devices. The US Food and Drug Administration (FDA) has ...
IRVINE, Calif.--(BUSINESS WIRE)--Axonics Modulation Technologies, Inc., the developer of the first rechargeable Sacral Neuromodulation (r-SNM™) System for the treatment of urinary and fecal ...
Fewer punctures and shorter surgical time reported for sacral neuromodulation with 3D printing and ultrasound localization. (HealthDay News) — For patients with neurogenic bladder and pelvic ...
SAN JOSE, Calif., June 18, 2025 /PRNewswire/ -- Neuspera ® Medical, Inc., the leading developer of integrated technologies powering the future of neuromodulation, today announced that the U.S. Food ...
IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel ...
The U.S. Food and Drug Administration (FDA) approved Axonics (NASDAQ:AXNX) fourth-generation rechargeable sacral neuromodulation system (SNM). SNM is a therapy to treat urinary incontinence. The ...
Axonics (NASDAQ:AXNX) said it acquired a lead placement solution from Radian which complements the company's existing sacral neuromodulation (SNM) offering. The company acquired the assets of Radian ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback